Resistance of casein-derived bioactive peptides to simulated gastrointestinal digestion

María del Mar Contreras^a, David Sanchez^b, María Ángeles Sevilla^b, Isidra Recio^a, Lourdes Amigo^{a}*

^a*Instituto de Investigación en Ciencias de la Alimentación (CIAL) (CSIC-UAM) (CEI, UAM-CSIC), Madrid, Spain*

^b*Departamento de Fisiología y Farmacología, Facultad de Farmacia, Universidad de Salamanca, Salamanca, Spain*

*Corresponding author: Tel.: + 34 91 0017 939; fax: +34 91 0017 905.

E-mail address: amigo@ifi.csic.es.

Abbreviations: ACE, angiotensin-converting enzyme; IC₅₀, concentration necessary to inhibit 50% of ACE activity; ORAC-FL, oxygen radical absorbance capacity-fluorescein; SBP, systolic blood pressure; SHR, spontaneously hypertensive rats.

Abstract

The resistance of six casein-derived peptides, including antihypertensive peptides RYLGY, AYFYPEL and YQKFPQY, to simulated gastrointestinal digestion and the effect on activity were evaluated. After digestion, peptides RYLGY, AYFYPEL, and YQKFPQY were partly hydrolyzed by digestive enzymes. From these, RYLGY and AYFYPEL maintained a potent ACE-inhibitory activity, with IC_{50} values as low as 9.3 and 4.7 $\mu\text{g mL}^{-1}$, respectively. Several of the digestion fragments, previously identified by HPLC-MS and synthesized, showed potent ACE-inhibitory, which could explain the *in vitro* activity of the digests. A notable antioxidant activity was also observed. Furthermore, since AYFYPEL was less susceptible to digestion, we focused on the antihypertensive activity in SHR of the main digestion fragments of RYLGY. Interestingly, these peptides showed moderate effects *in vivo*. This finding suggests that, besides undigested fraction that could also contribute in the *in vivo* effects of RYLGY and AYFYPEL, other minor fragments may participate.

1. Introduction

It is known that bioactive peptides may undergo physiological transformations that determine their bioavailability and activity in the organism. In fact, gastrointestinal digestion play an important role in the formation and degradation of bioactive peptides. Although *in vivo* methods, using animals or humans, usually provide the most accurate results, they are costly and time consuming. Therefore, a great interest has been dedicated on the development and application of *in vitro* approaches (Hur, Lim, Decker, & McClements, 2011). Sequential hydrolysis with pepsin and pancreatic extracts have been applied to mimic the gastrointestinal conditions and to evaluate the stability of angiotensin-converting enzyme (ACE) inhibitory peptides. This hydrolysis process together with *in vitro* studies with epithelial intestinal Caco-2 cells have allowed elucidating whether the released sequences have physiological relevance in blood pressure regulation. For instance, casein-derived peptides IPP and VPP, have been demonstrated to be highly resistant to digestive peptidases (Ohsawa et al., 2008), to be absorbed through intestinal epithelium (Foltz et al., 2008), reaching blood circulation in an intact and active form (Van Platerink, Janssen, Horsten, & Haverkamp, 2006; Foltz et al., 2007). Following a similar procedure, it was found that peptide LHLPLP resisted simulated gastrointestinal digestion, but it was hydrolysed by intestinal peptidases to the active form, HLPLP, prior to its absorption (Quirós, Dávalos, Lasunción, Ramos, & Recio, 2008; Quirós, Contreras, Ramos, Amigo, & Recio 2009). Interestingly, this pentapeptide was detected in human plasma samples after the consumption of a peptide-enriched drink (Van Platerink et al., 2006).

Gastrointestinal digestion may also lead the formation of active fragments from inactive or less active precursors. For example, the antihypertensive β -CN fragment, KVLPVP, was released from the inactive precursor KVLPVPQ after pancreatic digestion (Maeno, Yamamoto, & Takano, 1996). Miguel, Aleixandre, Ramos, & López-Fandiño (2006)

found, after simulated gastrointestinal digestion of egg white-derived peptides YAEERYPIL and RADHPFL, that released fragments YPI and RADHP might contribute on the *in vivo* effects of precursor peptides.

Two potent ACE-inhibitory peptides were identified in a peptic casein hydrolysate which corresponded to RYLGY [α_{S1} -CN f(90–94)], and AYFYPEL [α_{S1} -CN f(143–149)] (Contreras, Carrón, Montero, Ramos, & Recio, 2009). These peptides also exerted significant antihypertensive activity in spontaneously hypertensive rats (SHR) after both oral acute and long-term administration (Contreras et al., 2009; Sánchez et al., 2011). Additional cardiovascular benefits, such as significant improvement of the aorta and mesenteric acetylcholine relaxations, increase of the aortic endothelial nitric-oxide synthase (eNOS) expression and decrease of the left ventricular hypertrophy and interstitial fibrosis were also observed in SHR after administration of this casein hydrolysate (Sánchez et al., 2011). The hydrolysis process was scaled up to produce, under food grade conditions, an antihypertensive ingredient containing the most active peptides RYLGY and AYFYPEL (Contreras et al., 2011). Furthermore, no treatment-related toxicity was detected when casein hydrolysate was orally administered to Wistar rats at doses of 1000 mg kg⁻¹ for 4 weeks or 2000 mg kg⁻¹ in a single oral dose, which supports its safe use as functional ingredient (Anadón et al., 2010).

The main objective of the present study was to evaluate the stability of peptides previously identified in a casein hydrolysate against a process simulating physiological gastrointestinal digestion. Moreover, ACE-inhibitory, antihypertensive, and antioxidant activities of peptide fragments released during digestive process were also investigated in order to identify the *in vivo* active sequences.

2. Material and methods

2.1. Peptide synthesis

All peptides were prepared by conventional Fmoc solid-phase synthesis, using a 431A peptide synthesizer (Applied Biosystems, Uberlingen, Germany). The purity of these 16 peptides was verified by analytical RP-HPLC-MS (Quirós et al., 2008). Peptides corresponded to six casein-derived sequences found in a peptic hydrolysate: RYLGY, AYFYPEL, FVAPFPEV, VAPFPEVF, YQKFPQY, and HLPLPLL; and peptide fragments thereof generated during simulated gastrointestinal digestion: RY, YLG, RYLG, LGY, RYL, YLGY, AYFYPE, FYPEL, YQK, and FPQY were studied.

2.2. Simulated gastrointestinal digestion

The two stage-hydrolysis process simulating gastrointestinal digestion was carried out according to Gómez-Ruiz, Ramos, & Recio (2004) with the exception that the enzyme employed was pepsin (E.C. 3.4.23.1; 1:10,000; 570 U mg⁻¹) (Sigma, St. Louis, MO, USA). The simulated gastrointestinal digestion was carried out independently and in duplicate

2.3. Peptide sequencing by RP-HPLC-MS/MS

Digests were analysed by RP-HPLC-MS/MS using an Agilent 1100 HPLC System (Agilent Technologies, Waldbron, Germany) connected on-line to an Esquire 3000 quadrupole ion trap (Bruker Daltonik GmbH, Bremen, Germany) equipped with an electrospray ionisation source, as previously described (Contreras et al., 2010).

2.4. Measurement of ACE-inhibitory activity

ACE-inhibitory activity was measured by spectrophotometric assay of Cushman & Cheung (1971) with some modifications, as reported by Quirós et al. (2007). The ACE-inhibitory activity of the samples was expressed as IC₅₀ (peptide concentration required to inhibit the original ACE activity by 50%) and was determined in triplicate.

2.5. Measurement of antioxidant activity

Oxygen radical absorbance capacity-fluorescein (ORAC-FL) assay was based on the method applied by Dávalos, Gómez-Cordovés, & Bartolomé (2004) and reported by Contreras, Hernández-Ledesma, Amigo, Martín-Álvarez, Recio (2011). This assay was also performed in triplicate for each sample.

2.6. Measurement of antihypertensive activity

All the experiments were performed according to the European Union guidelines for the ethical care and use of laboratory animals (European Directive 86/609/CEE). Male SHR 12 week old (Elevage Janvier, Le Genest Saint Isle, France) were housed in groups of four rats and maintained at 23°C with 12 h light/dark cycles. The rats received, by oral administration using a canula, a single dose of the synthesized peptides (5 mg kg⁻¹ of body weight) dissolved in ultrapure water. Systolic blood pressure (SBP) was measured in awake rats using the CODA tail-cuff blood pressure system (Kent Scientific, Torrington, CT, USA) as was described previously (Sánchez et al., 2011). Blood pressure measurement was carried out before peptides administration, and at different times post-administration.

2.7. Statistical analysis

Data were expressed as mean $\pm$ standard error of the mean (SEM). Statistical calculations for significant differences between SBP before administration and the different times postadministration were performed by Student's t test for paired data and P values of less than 0.05 was considered significant. The GraphPad Prism 5 software program (GraphPad Software Inc., San Diego, California, USA) was used.

3. Results and discussion

3.1. Effect of simulated gastrointestinal digestion on ACE-inhibitory activity of casein peptides

The hydrolysis pattern of synthetic casein peptides subjected to simulated gastrointestinal digestion was evaluated by HPLC-MS/MS. This technique also allowed the identification of peptide sequences released during the digestive process. As shown in Fig. 1, six peptides were hydrolysed by digestive enzymes, but the degree of hydrolysis was different. Peptides RYLG, YQKFPQY, AYFYPEL, and FVAPFPEV were partially resistant to gastrointestinal digestion, whereas peptides VAPFPEVF and HLPLPLL were totally hydrolysed. After the action of digestive enzymes, 93% of peptide RYLG was hydrolysed, and RY, YLG, RYLG, YLGY, and RYL (Fig. 1A) appeared as major peptide fragments in the final digest. In the case of peptide AYFYPEL, 47% of undigested peptide remained intact at the end of the digestive process (Fig. 1B). This peptide and a shorter peptide, YFYPEL, were also found after simulated gastrointestinal digestion of different milk

products, such as infant formula (Hernández-Ledesma, Quirós, Amigo, & Recio, 2007), milk and yoghurt (Dupont et al., 2010). Moreover, a study performed in humans consuming milk or yoghurt demonstrated the presence of peptides AYFYPEL and YFYPEL in the stomach and duodenum, respectively, which demonstrate the resistance of this α_{s1} -casein fragment to human digestion (Chabance et al., 1998).

Several studies have suggested the role of amino acid proline making peptides less susceptible to proteolytic action (Quirós et al., 2007; Ohsawa et al., 2008), although the effect is dependent on the amino acid's position (Gómez-Ruiz et al., 2004). The presence of two inner prolines conferred resistance to the action of endopeptidases to peptides FVAPFPEV and VAPFPEVF, but their susceptibility to aminopeptidases and mainly carboxypeptidases was different. Peptide FVAPFPEV was weakly hydrolysed into VAPFPEV and FVAPFPE (Fig. 1C), whereas VAPFPEVF was completely hydrolysed, releasing the peptide VAPFPEV (Fig. 1D). In the case of YQKFPQY, trypsin could hydrolyse the peptide bond between lysine and phenylalanine, releasing the major fragments YQK and FPQY that were detected in the digest (Fig. 1E). HLPLPLL was also totally hydrolysed by digestive enzymes, releasing HLPLPL and a minor fragment that corresponded to the active form, HLPLP (Fig. 1F).

ACE-inhibitory activity of casein peptides, before and after digestion, is shown in Fig. 2. The most active sequences were RYLGY, AYFYPEL, YQKFPQY, and HLPLPLL, with IC_{50} values of 0.5, 5.9, 19.5 and 27.6 $\mu\text{g mL}^{-1}$, respectively. However, peptides FVAPFPEV and VAPFPEVF showed low inhibitory activity with IC_{50} values higher than 300 $\mu\text{g mL}^{-1}$. The action of digestive enzymes increased the activity of peptides AYFYEPL and FVAPFPEV, diminishing the activity of the rest of analysed peptides. It is noteworthy to mention the potent ACE-inhibitory activity measured in digests obtained from peptides RYLGY ($IC_{50} = 9.3 \mu\text{g mL}^{-1}$), and AYFYPEL ($IC_{50} = 4.7 \mu\text{g mL}^{-1}$). This activity was notably higher than that reported for other peptides obtained under similar conditions and exhibiting

antihypertensive activity *in vivo* (Quirós, Hernández-Ledesma, Ramos, Amigo, & Recio, 2005; Miguel et al., 2006; Hernández-Ledesma, Miguel, Amigo, Aleixandre, & Recio, 2007).

3.2. ACE-inhibitory and antioxidant activities of fragments released from casein peptides

The main fragments released from peptides RYLGY, AYFYPEL and YQKFPQY, after simulated gastrointestinal digestion, were chemically synthesized and their ACE-inhibitory and radical scavenging activities were evaluated (Table 1). After digestion of potent ACE-inhibitory peptide RYLGY, six sequences were identified, with three of them; LGY, YLGY, and RY showing IC₅₀ values lower than 55 µM. These sequences and the remaining precursor peptide could contribute to the activity detected in the final digest. Presence of Tyr at C-terminal position could favour the peptide binding to ACE (Igarashi et al., 2006; Tavares et al., 2011). The major peptides released from AYFYPEL, whose sequence were AYFYPE and FYPEL, showed moderate activity with IC₅₀ values of 260.82 µM and 80.60 µM, respectively. This result indicates that intact precursor peptide could be the sequence responsible for the high activity detected in the hydrolysate obtained at the end of simulated gastrointestinal digestion. Moreover, minor peptides could also contribute to this activity. Yang, Tao, Liu, & Liu (2007) found that dipeptide AY was a true inhibitor of ACE, with an IC₅₀ value of 14.2 µM.

In the case of sequence YQKFPQY, it was totally hydrolysed and major released fragments, YQK and FPQY showed higher IC₅₀ values (312.23 µM and 300.74 µM, respectively) than that of the precursor peptide (20.08 µM), thus explaining the decrease of the activity detected in the final digest.

Precursor casein peptides (RYLGY, AYFYPEL, and YQKFPQY), and their derived fragments after action of digestive enzymes showed ORAC-FL values higher than that of

Trolox, used as standard antioxidant. These values were ranged from 1.38 to 4.16 μmol of Trolox μmol^{-1} of peptide (Table 1). Presence of Tyr in all these peptides could determinate the high antioxidant activity detected. This amino acid had been previously described as responsible for radical scavenging activity of food-derived peptides (Dávalos, Miguel, Bartolomé, & López-Fandiño, 2004; Hernández-Ledesma, Dávalos, Bartolomé, & Amigo, 2005; Hernández-Ledesma, Amigo, Recio, & Bartolomé, 2007). Moreover, those peptides containing two residues of Tyr were the most potent sequences identified in this study. In the case of peptides RYLGY and YQKFPQY, precursor sequences were more active than the released peptides, which could be due to the presence of two Tyr within the sequence, one of them being a C-terminal amino acid. However, peptide AYFYPE released during digestion process showed an ORAC-FL value of 4.16 μmol of Trolox μmol^{-1} of peptide, 1.3-times higher than that shown by its precursor peptide AYFYPEL. Deletion of Leu at C-terminal position enhanced antioxidant activity, leaves Tyr at antepenultimate position and it seems to improve radical scavenging.

3.3. Antihypertensive activity of casein-peptides derived fragments

Since peptide RYLGY showed potent antihypertensive activity but low resistance to enzymatic digestion, this peptide was selected to investigate its antihypertensive activity of the major released fragments, i.e., RYLG, YLGY, RY, and YLG, after gastrointestinal digestion. Fig. 3 shows the changes in systolic blood pressure (SBP) of SHR after acute administration of 5 mg peptide kg^{-1} of body weight. The precursor peptide, RYLGY, notably reduced SBP after 4 post-administration, obtaining decreases around 20 mm Hg. All peptide fragments, except YLG, exerted significant hypotensive activity and no statistically significant differences were found among peptides (except for YLG). Among the released

fragments, RYLG exhibited significant decreases ($p<0.05$) at 2, 4 and 8 h post-administration; RY at 4 and 8 h post-administration and YLGY at 2, 4, 6 and 8 h post-administration. Three of the peptides assayed have Tyr as C-terminal residue as other food derived peptides that have demonstrated to be absorbed and reach blood circulation in an intact form and to exert hypotensive effects in SHR (Matsufuji et al., 1995; Matsui et al., 2002; Van Platerink et al., 2006; Foltz, et al., 2007). The antihypertensive activity on SHR of peptide RY had been previously demonstrated and its effects continued for 30 h after oral administration (Saito, Wanezaki, & Imayasu, 1994).

Peptide RYLG reached the maximum antihypertensive effect after 6 h post-administration ($-18. \pm 5$ mm Hg). However, ACE-inhibitory activity of this peptide was low, with an IC_{50} value of 224.7 μ M. This result opens up the possibility that, besides ACE-inhibitory activity, other molecular mechanisms underlie the mode of action of this peptide. Increased production of superoxide anion and hydrogen peroxide, reduced nitric oxide synthesis, and decreased bioavailability of antioxidants have been related with hypertension (Touyz, 2004; Sánchez et al., 2011). Supplementation with antioxidants have been shown to decrease blood pressure in animal models and humans with essential hypertension (Vasdev, & Gill, 2005). Peptide RYLG showed a notable radical scavenging activity, indicating that its antioxidant properties might contribute to its antihypertensive effect. Moreover, this peptide presents high homology with sequence RYLGYL, α_{S1} -CN f(90–95), which has previously been described as an opioid (Loukas, Varoucha, Zioudrou, Streaty, & Klee, 1983). Hypotensive and vasodilator effects exerted by opioid peptides, such as of α -La f(50-53) (YGLF), could be mediated by interaction with opioid receptors (Nurminen et al., 2000).

4. Conclusions

Antihypertensive peptides RYLGY and AYFYPEL partly resisted the action of enzymes during a process simulating gastrointestinal conditions. High ACE-inhibitory activity of these peptides was still observed after simulated gastrointestinal digestion, with IC_{50} values lower than $10 \mu M mL^{-1}$. All studied peptide fragments exhibited radical-scavenging activity, being AYFYPE the most active peptide, and several of them also showed ACE-inhibitory activity, such as LGY, YLGY and RY. The antihypertensive activity in SHR of RYLGY peptide was as high as that found after oral administration of RYLG, YLGY, and RY, main digestion fragments. This result highlighted that in addition to the undigested fraction, other minor fragments and their combined action could contribute in the *in vivo* effects of RYLGY. Although ACE-inhibition could be responsible of the antihypertensive activity, other mechanisms such as vasodilatation, antioxidant and opioid activity cannot be discarded. Thus, further work will be needed to clarify the physiological relevance and mechanism of other minor digestion fragments and the molecular mechanism of action of RYLGY.

Acknowledgments

This work has received financial support from the projects AGL2011-24643, Consolider Ingenio 2010 FUN-C-Food CSD2007-063 from Ministerio de Ciencia e Innovación, and project P2009/AGR-1469 from Comunidad de Madrid. The authors are participants in the FA1005COST Action INFOGEST on food digestion.

References

- Anadón, A., Martínez, M. A., Ares, I., Ramos, E., Martínez-Larrañaga, M. R., Contreras, M. M., Ramos, M., & Recio I. (2010). Acute and repeated dose (4 weeks) oral toxicity studies of two antihypertensive peptides, RYLGY and AYFYPEL, that correspond to fragments (90–94) and (143–149) from α_{s1} -casein. *Food and Chemical Toxicology*, 48, 1836-1845.
- Contreras, M. M., Carrón, R., Montero, M. J., Ramos, M., & Recio, I., (2009). Novel casein-derived peptides with antihypertensive activity. *International Dairy Journal*, 19, 566-573.
- Contreras, M. M., Gómez-Sala, B., Martín-Álvarez, P. J., Amigo, L., Ramos, M., & Recio, I. (2010). Monitoring the large-scale production of the antihypertensive peptides RYLGY and AYFYPEL by HPLC-MS. *Analytical & Bioanalytical Chemistry*, 397, 2825-2832.
- Contreras, M. M., Hernández-Ledesma, B., Amigo, L., Martín-Álvarez, P. J., & Recio, I. (2011). Production of antioxidant hydrolyzates from a whey protein concentrate with thermolysin: Optimization by response surface methodology. *LWT-Food Science and Technology*, 44, 9-15
- Contreras, M. M., Sevilla, M. A., Monroy-Ruiz, J., Amigo, L., Gómez-Sala, B., Molina, E., Ramos, M., & Recio, I. (2011). Food-grade production of an antihypertensive casein hydrolysate and resistance of active peptides to drying and storage. *International Dairy Journal*, 21, 470-476.
- Cushman, D. W., & Cheung, H. S. (1971). Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. *Biochemical Pharmacology*, 20, 1637-1648.

- Chabance, B., Marteau, P., Rambaud, J.C., Migliore-Samour, D., Boynard, M., Perrotin, P., Guillet, R, Jollès, P, & Fiat, A.M. (1998), Casein peptide release and passage to the blood in humans during digestion of milk or yogurt. *Biochimie*, 80, 155-165.
- Dávalos, A., Gómez-Cordovés, C., & Bartolomé, B. (2004). Extending applicability of the oxygen radical absorbance capacity (ORAC-Fluorescein) assay. *Journal of Agricultural and Food Chemistry*, 52, 48-54.
- Dávalos, A., Miguel, M., Bartolomé, B., & López-Fandiño, R. (2004). Antioxidant activity of peptides derived from egg white proteins by enzymatic hydrolysis. *Journal of Food Protection*, 67, 1939-1944.
- Dupont, D., Mandalari, G., Molle, D., Jardin, J., Rolet-Répécaud, O., Duboz, G., Leónil, J., Mills, E. N. C., & Mackie, A.R. (2010). Food processing increases casein resistance to simulated infant digestion. *Molecular Nutrition & Food Research*, 54, 1677-1689.
- Foltz, M., Cerstiaens, A., van Meensel, A., Mols, R., van der Pijl, P. C., Duchateau, G. S. M. J. E., & Augustijns, P. (2008). The angiotensin converting enzyme inhibitory tripeptides Ile-Pro-Pro and Val-Pro-Pro show increasing permeabilities with increasing physiological relevance of absorption models. *Peptides*, 29, 1312-1320.
- Foltz, M., Meynen, E. E, Bianco, V., van Platerink, C., Koning, T. M. M. G., & Kloek, J. (2007). Angiotensin converting enzyme inhibitory peptides from a lactotripeptide-enriched milk beverage are absorbed intact into the circulation. *Journal of Nutrition*, 137, 953-958.
- Gómez-Ruiz J. A., Ramos, M., & Recio, I. (2004). Angiotensin-converting enzyme-inhibitory of peptides isolated from Manchego cheese. Stability under simulated gastrointestinal digestion. *International Dairy Journal*, 14, 1075-1080.
- Hernández-Ledesma, B., Amigo, L., Recio, I., & Bartolomé, B. (2007). ACE-inhibitory and radical scavenging activity of peptides derived from beta-lactoglobulin f(19-25).

Interactions with ascorbic acid. *Journal of Agricultural and Food Chemistry*, 55, 3392-3397.

Hernández-Ledesma, B., Dávalos, B., Bartolomé, B., Amigo, L. (2005). Preparation of antioxidant enzymatic hydrolysates from α -lactalbumin and β -lactoglobulin. Identification of active peptides by HPLC-MS/MS. *Journal of Agriculture and Food Chemistry*, 53, 588-593.

Hernández-Ledesma, B., Miguel, M., Amigo, L., Aleixandre, M. A., & Recio, I. (2007). Effect of simulated gastrointestinal digestion on the antihypertensive properties of synthetic β -lactoglobulin peptide sequences. *Journal of Dairy Research*, 74, 336–339.

Hernández-Ledesma, B., Quirós A, Amigo, L., & Recio, I. (2007). Identification of bioactive peptides after digestion of human milk and infant formula with pepsin and pancreatin. *International Dairy Journal*, 17, 42–49.

Hur, S. J., Lim, B. O., Decker, E. A., & McClements, D. J. (2011). In vitro human digestion models for food applications. *Food Chemistry*, 125, 1-12.

Igarashi, K., Yoshioka, K., Mizutani, K., Miyakoshi, M., Murakami, T., & Akizawa, T. (2006). Blood pressure-depressing activity of a peptide derived from silkworm fibroin in spontaneously hypertensive rats. *Bioscience Biotechnology and Biochemistry*, 70, 517-520.

Loukas, S., Varoucha, D., Zioudrou, C., Streaty, R. A., & Klee, W. A. (1983). Opioid activities and structures of alpha-casein-derived exorphins. *Biochemistry*, 22, 4567-4573.

Maeno, M., Yamamoto, N., & Takano, T. (1996). Identification of an antihypertensive peptide from casein hydrolysate produced by a proteinase from *Lactobacillus helveticus* CP790. *Journal of Dairy Science*, 79, 1316-1321.

357 Matsufuji, H., Matsui, T., Ohshige, S., Kawasaki, T., Osajima, K., & Osajima, Y. (1995).
 358 Antihypertensive effects of angiotensin fragments in SHR. *Bioscience Biotechnology*
 359 *and Biochemistry*, 59, 1398-1401.

360 Matsui, T., Tamaya, K., Seki, E., Osajima, K., Matsumoto, K., Kawasaki, T. (2002).
 361 Absorption of Val-Tyr with in vitro angiotensin I-converting enzyme inhibitory activity
 362 into the circulating blood system of mild hypertensive subjects. *Biological &*
 363 *Pharmaceutical Bulletin*, 25, 1228–1230.

364 Miguel, M., Aleixandre, M. A., Ramos, M., López-Fandiño, R. (2006). Effect of simulated
 365 gastrointestinal digestion on the antihypertensive properties of ACE-inhibitory peptides
 366 derived from ovalbumin. *Journal of Agricultural of Food Chemistry*, 54, 726-731.

367 Nurminen, M. L., Sipola, M., Kaarto, H., Pihlanto-Leppala, A., Piilola, K., Korpela, R.,
 368 Tossavainen, O., Korhonen, H., & Vapaatalo, H.. (2000). α -lactorphan lowers blood
 369 pressure measured by radiotelemetry in normotensive and spontaneously hypertensive
 370 rats. *Life Sciences*, 66, 1535-1543.

371 Ohsawa, K., Satsu, H., Ohki, K., Enjoh, M., Takano, T., & Shimizu, M. (2008). Producibility
 372 and digestibility of antihypertensive β -casein tripeptides, Val-Pro-Pro and Ile-Pro-Pro,
 373 in the gastrointestinal tract: Analyses using an in vitro model of mammalian
 374 gastrointestinal digestion. *Journal of Agricultural and Food Chemistry*, 56, 854-858.

375 Quirós, A., Contreras, M. M., Ramos, M., Amigo, L., & Recio, I. (2009). Stability to
 376 gastrointestinal enzymes and structure-activity relationship of beta-casein-peptides with
 377 antihypertensive properties. *Peptides*, 30, 1848-1853.

378 Quirós, A., Davalos, A., Lasunción, M. A., Ramos, M., & Recio, I. (2008). Bioavailability of
 379 the antihypertensive peptide LHLPLP: Transepithelial flux of HLPLP. *International*
 380 *Dairy Journal*, 18, 279-286.

381 Quirós, A., Hernández-Ledesma, B., Ramos, M., Amigo, L., & Recio, I. (2005). Angiotensin-
382 converting enzyme inhibitory activity of peptides derived from caprine kefir. *Journal of*
383 *Dairy Science*, 88, 3480-3487.

384 Quirós, A., Ramos, M., Muguerza, B., Delgado, M. A., Miguel, M., Aleixandre, A., & Recio,
385 I. (2007). Identification of novel antihypertensive peptides in milk fermented with
386 *Enterococcus faecalis*. *International Dairy Journal*, 17, 33-41.

387 Saito, Y., Wanezaki, K., Kawato, A., Imayasu, S. (1994). Antihypertensive effects of peptide
388 in sake and its by-products on spontaneously hypertensive rats. *Bioscience*
389 *Biotechnology and Biochemistry*, 58, 812-816.

390 Sánchez, D., Kassin, M., Contreras, M. M., Carrón, R., Recio, I., Montero, M. J., & Sevilla,
391 M. A. (2011). Long-term intake of a milk casein hydrolysate attenuates the development
392 of hypertension and involves cardiovascular benefits. *Pharmacological Research*, 63,
393 398-404.

394 Tavares, T., Contreras, M. M., Amorim, M., Pintado, M., Recio, I., & Malcata, F. X. (2011).
395 Novel whey-derived peptides with inhibitory effect against angiotensin-converting
396 enzyme: In vitro effect and stability to gastrointestinal enzymes. *Peptides*, 32, 1013-
397 1019.

398 Touyz, R. M. (2004). Reactive oxygen species, vascular oxidative stress and redox signaling
399 in hypertension: what is the clinical significance?. *Hypertension*, 44, 248-252.

400 Van Platerink, C. J., Janssen, H. G. M., Horsten, R., & Haverkamp, J. (2006). Quantification
401 of ACE inhibiting peptides in human plasma using high performance liquid
402 chromatography-mass spectrometry. *Journal of Chromatography B*, 830, 151-157.

403 Vasdev, S., & Gill, V., (2005). Antioxidants in the treatment of hypertension. *International*
404 *Journal of Angiology*, 14, 60-73.

405 Yang, Y., Tao, G., Liu, P., Liu, J. (2007). Peptide with angiotensin I-converting enzyme
406 inhibitory activity from hydrolyzed corn gluten meal. *Journal of Agriculture and Food*
407 *Chemistry*, 55, 7891-7895.

FIGURE CAPTIONS

Figure 1. RP-HPLC chromatograms and peptide fragments released after simulated gastrointestinal digestion of synthetic peptides: (A) RYLG_Y; (B) AYFYPEL; (C) FVAPFPEV; (D) VAPFPEVF; (E) YQKFPQY and (F) HLPLPLL.

Figure 2. Angiotensin-converting enzyme-inhibitory activity, expressed as IC₅₀ (μg mL⁻¹), of casein derived-peptides before and after simulated gastrointestinal digestion. Data are expressed as mean ± standard deviation (n = 3).

Figure 3. Effects of synthetic peptides RYLG_Y, RYLG, RY, YLG_Y, and YLG on systolic blood pressure (SBP) of spontaneously hypertensive rats (SHR) at different times after oral administration at the same dose. Data are expressed as mean ± SEM. Student's t test was used to compare different times post-administration (n = 6, *P < 0.05).